



## Thursday, 05 February 2009

**09.00-10.15**

Satellite Symposium

Chairs: *Javier Garau, Toni Torres (Spain)*

**Fluoroquinolones: contemporary roles in CAP**

**Session I:** Chairmans' introduction:

**What is the case for fluoroquinolones in the treatment of LRTI?**

*Antoni Torres (Spain)*

- Fluoroquinolone selection: key efficacy predictors.  
*Don Low (Canada)*
- Fluoroquinolone selection: appropriate benefit-risk profiles.  
*Paul Tulkens (Belgium)*

**Panel discussion**

**10.15-10.30**

*Coffee break*

**10.30-12.00**

**Session II:** Chairmans' introduction:

**Treatment of hospitalised CAP patients with fluoroquinolones: guidelines, evidence, and experience**

*Javier Garau (Spain)*

- The appropriate role of fluoroquinolones in hospitalised CAP.  
*Lionel Mandell (Canada)*
- The value of moxifloxacin in the hospital: the evidence for CAP.  
*Tobias Welte (Germany)*

**Panel discussion**



- 13.00-13.15**     **RTI5 Chairmen's Introduction:**  
Prof.s.: *Antoni Torres, Javier Garau (Spain)*
- 13.15-14.00**     Keynote Lecture  
**Severe CAP: therapy beyond chemotherapy**  
*Antoni Torres (Spain)*
- 14.00-16.00**     Symposium 1  
Chairs: *Hartmut Lode (Germany)*  
*Alisdair MacGowan (U.K.)*  
**Issues in the management of severe CAP**
- Diagnosis of Severe Pneumonia (sCAP)  
*Santiago Ewig (Germany)*
  - sCAP: effectiveness of the Guidelines  
*Mark Woodhead (U.K.)*
  - PK/PD of the new agents  
*Alasdair MacGowan (U.K.)*
  - sCAP: monotherapy versus combination  
*Hartmut Lode (Germany)*
  - The need for new antibiotics for sCAP  
*Jordi Rello (Spain)*
  - Panel Discussion
- 16.00-16.30**     *Refreshment Break*
- 16.30-17.00**     Plenary 1  
**RTI update: advances since the 2007 Forum**  
*Ethan Rubinstein (Canada)*
- 17.00-17.30**     Plenary 2  
**Advances in Cystic Fibrosis**  
*Niels Hoiby (Denmark)*
- 17.30-18.00**     BSAC Lecture  
**CA/MRSA in RTIs in Europe and North America**  
*Dilip Nathwani (U.K.)*
- 18.00-19.00**     *Welcome Cocktail*



Friday, 06 February 2009

08.30-09.00

Plenary 3

Chairs: *Francesco Blasi, Carlo Grassi (Italy)*

**Mycobacteria in respiratory disease**

*Giovanni Battista Migliori (Italy)*

9.00-11.00

Symposium 2

Chairs: *Toni Torres (Spain), Peter Ball (U.K.)*

**Inhalation approaches to treating Gram-negative pathogens in infected airways**

- Issues surrounding inhaled antibiotic treatment for HAP/VAP  
*Michael Niederman (USA)*
- Evidence to support inhaled treatment of HAP/VAP  
*Jean Chastre (France)*
- Can inhaled antibiotics reduce exacerbations in chronic airway disease?  
*Stuart Elborn (U.K.)*

11.00-11.30

*Coffee Break*

11.30-13.00

Plenary 4

**Where do we go with PROs?**

*Paul Jones (U.K.)*

**Pre-lunch Colloquium**


Chairs: *Robert Wilson (U.K.), Marc Miravittles (Spain)*

**Placebo-controlled trials in AECB (and other RTIs)**

- Regulatory requirements (FDA/EMEA)  
*Glenn Tillotson (USA)*
- Comparison with non-inferiority studies  
*Rob Wilson (U.K.)*
- Clinical interpretation  
*Marc Miravittles (Spain)*

13.00-14.00

*Lunch*



**14.00-15.30**

Symposium 3

Chairs: *Javier Garau (Spain), Francesco Blasi (Italy)*

**Innovative Approaches to common RTI's:  
the role of Ultra Short Course Therapy**

- Appropriate utilization of antimicrobials in the out-patient setting - a challenge for clinicians  
*Don Low (Canada)*
- Risk stratification and early empirical therapy of common RTI's  
*Tom File (USA)*
- Revolutionizing treatment of common RTIs - historical perspectives and technological advances  
*Francesco Blasi (Italy)*

**15.30-16.00**

*Refreshment Break*

**16.00-16.30**

Plenary 5

**Serious Gram-positive infections: effective therapy despite prevalent resistance**

*Javier Garau (Spain)*

**16.30-18.00**

Symposium 4

Chairs: *TBA*

**Inflammatory responses in CAP: therapeutic interventions**

- Cytokine cascade in pneumococcal pneumonia  
*Esther Calbo (Spain)*
- Biological markers in CAP  
*Rosario Menendez (Spain)*
- Systemic cytokines as prognostic factors in CAP: ?  
*Tobias Welte (Germany)*



## Saturday, 07 February 2009

- 08.40-09.15** Plenary 6  
**Management of RTI in Primary Care: the Grace Study**  
*Chris Butler (Wales)*
- 09.15-10.15** **Debate: can there be global guidelines?**  
Moderator: *Richard Wise (U.K.)*  
Proposing the motion: *Mark Woodhead (U.K.)*  
Opposing the motion: *Tom File (USA)*
- 10.15-10.40** *Coffee break*
- 10.40-11.40** **Point and counterpoint: HealthCare-associated Pneumonia: evolving definitions and management**
- North American perspective  
*Mike Niederman (USA)*
  - European perspective  
*Santiago Ewig (Germany)*
- 11.40-12.10** Closing Plenary Session  
**Bypassing vaccines: the resurgence of the pneumococcus**  
*Ake Ortqvist (Sweden)*
- 12.15** Close of Meeting: Chairmen